Amgen’s T-VEC Gets Negative FDA Report Card; Treatment Subgroup Could Be Salvation
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory Committee will weigh concerns about study design and results of Amgen’s metastatic melanoma immunotherapy.